Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02680067 · ClinicalTrials.gov registry record · Phase 1

NIR Fluorescence Imaging of Lymphatic Transport Using ICG

A Phase 1 study, sponsored by University of Rochester.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target

NCT02680067 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 23 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02680067, a Phase 1 study, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target

Study Summary

In this phase 1 study, the lymphatic transport will be examined using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities in healthy individuals using a MultiSpectral Imaging System (MSImager).

Interventions

  • DRUG Indocyanine Green
  • DEVICE MultiSpectral Imaging System

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2015-12-08
Est. Completion 2022-07
Phase Phase 1

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT02680067

The ClinicalTrials.gov registry entry for NCT02680067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Indocyanine Green is the first listed.

NCT02680067 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02680067 about?

NCT02680067 is a clinical study titled "NIR Fluorescence Imaging of Lymphatic Transport Using ICG". In this phase 1 study, the lymphatic transport will be examined using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities in healthy individuals using a MultiSpectral Imaging System (MSImager).

What is the current status of trial NCT02680067?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2015-12-08. Estimated completion is 2022-07.

What interventions are being tested in trial NCT02680067?

The interventions under investigation include: Indocyanine Green (DRUG), MultiSpectral Imaging System (DEVICE).

Who is sponsoring clinical trial NCT02680067?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.